1. Novel treatment planning approaches to enhance the therapeutic ratio: targeting the molecular mechanisms of radiation therapy

   • M. Protopapa
   • V. Kouloulias
   • A. Zygogianni

   Review Article 28 June 2019 Pages: 447 - 456

   

2. Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients

   • J. Feliu
   • V. Heredia-Soto
   • M. J. Molina-Garrido

   Review Article 25 June 2019 Pages: 457 - 467

3. Evaluation of axillary lymph node metastasis burden by preoperative ultrasound in early-stage breast cancer with needle biopsy-proven metastasis

   • X. Wang
   • L. Chen
   • B. Zhang

   Research Article 18 June 2019 Pages: 468 - 473

   

4. Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis

   • N. Wu
   • F. Fu
   • C. Wang

   Research Article Open access 20 June 2019 Pages: 474 - 485

   

5. The effect of fenofibrate, a PPARα activator on toll-like receptor-4 signal transduction in melanoma both in vitro and in vivo

   • N. Dana
   • S. Haghjooy Javanmard
   • G. Vaseghi

   Research Article 07 June 2019 Pages: 486 - 494

   

6. First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial

   • G. Quintero Aldana
   • M. Salgado
   • the Galician Oncological Research Group (GGIO)

   Research Article 06 July 2019 Pages: 495 - 502

   

7. Human colorectal cancer derived-MSCs promote tumor cells escape from senescence via P53/P21 pathway

   • G. Li
   • R. Zhang
   • Y. Feng

   Research Article 19 June 2019 Pages: 503 - 511

   

8. Resection of liver metastases from breast cancer: a multicentre analysis

   • X. He
   • Q. Zhang
   • L. Wang

   Research Article Open access 22 June 2019 Pages: 512 - 521

   

9. Stromal fibroblast-derived MFAP5 promotes the invasion and migration of breast cancer cells via Notch1/slug signaling

   • Z. Chen
   • X. Yan
   • H. Kang

   Research Article 12 June 2019 Pages: 522 - 531

   

10. Red and processed meat consumption and esophageal cancer risk: a systematic review and meta-analysis

    • Z. Zhao
    • F. Wang
    • C. Zhang

    Research Article 03 July 2019 Pages: 532 - 545

    

11. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification

    • J. Cornillie
    • A. Wozniak
    • P. Schöffski

    Research Article 14 June 2019 Pages: 546 - 554

    

12. Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients

    • B. Fox
    • M. de Toro Carmena
    • I. Márquez-Rodas

    Research Article 29 June 2019 Pages: 555 - 562

    

13. ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22/AKT signaling

    • X. Xuan
    • J. Zhou
    • W. Yang

    Research Article 15 June 2019 Pages: 563 - 575

    

14. The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients

    • K. Chen
    • J. Quan
    • Z. Chen

    Research Article 17 June 2019 Pages: 576 - 584

    

15. Breast cancer and cytomegalovirus

    • A. K. Richardson
    • L. C. Walker
    • M. J. Currie

    Research Article 29 June 2019 Pages: 585 - 602

16. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

    • A. Passaro
    • P. Mancuso
    • F. Bertolini

    Research Article 28 June 2019 Pages: 603 - 611

    

17. Outpatient management of incidental pulmonary embolism in cancer patient

    • Andrés J. Muñoz Martín
    • Magdalena Carmen Ruiz Zamorano
    • Miguel Martín Jiménez

    Brief Research Article 13 June 2019 Pages: 612 - 615

18. Bemiparin as a long-term treatment for venous thrombosis in cancer patients: the ELEBAMA study

    • E. Pina
    • M. Antonio
    • C. Tebe

    Brief Research Article 19 June 2019 Pages: 616 - 620

    

19. Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

    • A. Passaro
    • P. Mancuso
    • F. Bertolini

    Author Correction 20 August 2019 Pages: 621 - 621